Ivacaftor治疗慢性阻塞性肺疾病:2期随机对照试验结果
这项2期随机双盲安慰剂对照试验纳入40例中重度COPD伴慢性支气管炎症状患者,随机接受Ivacaftor 150 mg每日两次(n=30)或安慰剂(n=10)治疗12周。结果显示Ivacaftor安全可耐受,但未改善汗液氯离子、全肺黏液纤毛清除、肺功能或呼吸道症状。
要点
- Ivacaftor 150 mg每日两次治疗12周在COPD患者中安全可耐受
- 未改善CFTR活性、黏液清除、肺功能或呼吸道症状
- 12小时AUC仅为CF囊性纤维化既往报告值的72%,提示需进一步剂量研究
核心结论
- Ivacaftor在COPD患者中安全且耐受良好,但未改善CFTR活性或黏液清除指标。
- 因血药浓度低于囊性纤维化同剂量水平且野生型CFTR调控不同于G551D,需进一步剂量确定研究。
研究设计与样本
- 2期随机双盲安慰剂对照试验,纳入40例中重度COPD伴慢性支气管炎症状患者,随机分为Ivacaftor 150 mg每日两次组(n=30)与安慰剂组(n=10),治疗12周。
- 主要终点为Ivacaftor安全性与药代动力学,次要终点包括CFTR活性与临床结局指标。
主要发现
- Ivacaftor安全可耐受,两组不良事件发生率相似。
- 最常见不良事件为Ivacaftor组腹泻、安慰剂组COPD急性加重。
- 药代动力学分析显示12小时平均AUC为既往囊性纤维化报告值的72%。
- Ivacaftor未改善汗液氯离子、全肺黏液纤毛清除、肺功能或呼吸道症状。
关键数值与推荐
- Ivacaftor剂量为150 mg每日两次,疗程12周。
- 12小时平均AUC为既往囊性纤维化报告值的72%。
- 试验注册号NCT03085485。
临床怎么用
- 目前证据不支持Ivacaftor用于中重度COPD伴慢性支气管炎的常规治疗。
- 需进一步剂量确定研究以评估CFTR增效剂在COPD中的疗效。
局限性
- 样本量小(共40例,Ivacaftor组30例、安慰剂组10例)。
- 为2期探索性试验,主要终点为安全性与药代动力学。
- 所达到的血药浓度低于囊性纤维化同剂量水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Patients with chronic obstructive pulmonary disease (COPD) exhibit acquired CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction. CFTR modulators may improve outcomes in patients with COPD, although recent data regarding the magnitude of benefit have been inconclusive, and effects on mucociliary clearance are unknown. Objective: We conducted a phase 2, randomized, double-blind, placebo-controlled trial to determine safety and tolerability and explore the potential mechanism of ivacaftor for the treatment of patients with COPD. Methods: We randomized 40 patients with moderate to severe COPD and symptoms of chronic bronchitis to ivacaftor (n = 30) or placebo (n = 10) 150 mg twice daily for 12 weeks. Primary endpoints included evaluation of the safety of ivacaftor and pharmacokinetics. Secondary endpoints included measures of CFTR activity and clinical outcomes. Measurements and Main Results: Ivacaftor was safe and tolerable, with similar rates of adverse events between groups. The most common adverse events were diarrhea in the ivacaftor group and acute COPD exacerbation in the placebo group. Pharmacokinetic analysis showed the mean area under the curve over 12 hours to be 72% of the previously reported value in cystic fibrosis. Treatment with ivacaftor did not improve sweat chloride, whole-lung mucociliary clearance, lung function, or respiratory symptoms. Conclusions: Ivacaftor was safe and well tolerated but did not improve measures of CFTR activity or mucus clearance. As serum concentrations achieved were lower than observed in cystic fibrosis at the same dose, and modulation of wild-type CFTR differs from G551D, further dose determination studies are needed to better understand the treatment efficacy of CFTR potentiators in COPD. Clinical trial registered with www.clinicaltrials.gov (NCT03085485).
引用
- Vijaykumar, Solomon, Guimbellot, et al. Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial. Am J Respir Crit Care Med. 2025. PMID: 39316773. doi:10.1164/rccm.202407-1302OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。